Your browser doesn't support javascript.
loading
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma.
Kaseb, Ahmed Omar; Kappadath, S Cheenu; Lee, Sunyoung S; Raghav, Kanwal Pratap; Mohamed, Yehia I; Xiao, Lianchun; Morris, Jeffrey S; Ohaji, Chimela; Avritscher, Rony; Odisio, Bruno C; Kuban, Joshua; Abdelsalam, Mohamed E; Chasen, Beth; Elsayes, Khaled M; Elbanan, Mohamed; Wolff, Robert A; Yao, James C; Mahvash, Armeen.
Afiliación
  • Kaseb AO; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kappadath SC; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee SS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Raghav KP; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mohamed YI; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Morris JS; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Ohaji C; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Avritscher R; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Odisio BC; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kuban J; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Abdelsalam ME; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chasen B; Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Elsayes KM; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Elbanan M; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wolff RA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yao JC; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mahvash A; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Hepatocell Carcinoma ; 8: 1129-1145, 2021.
Article en En | MEDLINE | ID: mdl-34527608
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies Idioma: En Revista: J Hepatocell Carcinoma Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies Idioma: En Revista: J Hepatocell Carcinoma Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos